ImmunityBio Inc. (IBRX): One of the Most Shorted Mid-Cap Stocks to Buy Now

ImmunityBio Inc. (NASDAQ:IBRX) is one of the most shorted mid-cap and small-cap stocks to buy now. On May 19, Immunitybio Inc. (NASDAQ:IBRX) confirmed the US Food and Drug Administration accepted for review the supplemental Biologics License Application (sBLA)  for ANKTIVA  Plus BCG in BCG Unresponsive Non-Muscle Invasive Bladder Cancer.

This is why ImmunityBio Inc. (IBRX) is One of the Most Shorted Mid Cap Stocks to Buy

The supplemental BLA was accepted for review based on additional scientific data that the company provided to the FDA. The data detailed overlapping features of papillary and CIS disease that pave the way for the expansion of the already approved indication of ANKTIVA for the treatment of patients with BCG-unresponsive NMIBC with papillary tumors.

At the International Society for Pharmacoeconomics and Outcomes Research 2026 conference, Immunitybio detailed the cost savings of ANTKIVA  in the treatment of non-muscle-invasive bladder cancer patients with carcinoma in situ. ANKTIVA plus BCG showed cost savings per cystectomy of $109,622 at Year 1, $151,438 at Year 2, and $60,393 at Year 3 compared to TAR-200. The cost savings resulted from lower drug acquisition and administration costs.

ImmunityBio Inc. (NASDAQ:IBRX) is a clinical-stage biotechnology company developing next-generation immunotherapies and cell therapies that activate a patient’s immune system to fight cancer and infectious diseases. Their goal is to stimulate both innate and adaptive immune systems to generate long-lasting immunological memory.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Small Cap Stocks With Huge Growth Potential and Renaissance Technologies Returns, AUM, CEO and Top 10 Semiconductor Stock Picks.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1